A controlled-release formulation of the 5-hydroxytryptamine 3 (5-HT3) antagonist granisetron, in which granisteron is encapsulated in a biodegradable poly(ortho ester) polymer, with antiemetic activity. Upon subcutaneous administration, APF530 slowly erodes and releases the active ingredient granisetron over a period of approximately 5 days. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in the suppression of nausea and vomiting.
Learn more about APF530
Latest research - APF530
This WikiMD article APF530 is a stub. If you are familiar with the topic APF530, you can help us. Paid editors welcome!
APF530 is part of WikiMD's free ^articles!
^APF530 (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.